

## Information About the IL13Rα2 CAR T Cell Study

**Study Name:** *Phase 1 Dose Escalation Study of Systemically Administered IL13Rα2 Chimeric Antigen Receptor (CAR) T Cells after a Nonmyeloablative Conditioning Regimen in Patients with Metastatic Melanoma and Other Solid Tumors*

We are conducting a clinical trial using CAR T cells for patients with solid tumors. These are immune cells that have been genetically modified to recognize and attack tumor cells expressing IL13Rα2, a protein found on the surface of some cancers.

### About the Study

CAR-T therapy is a form of personalized immunotherapy that uses a patient's own modified T cells to find and destroy cancer cells. Unlike existing immunotherapies, CAR-T cells directly target tumor-specific proteins, which may help overcome resistance to standard treatments.

The IL13Rα2 protein is found at high levels in patients with neuroendocrine tumors, pheochromocytoma, adrenocortical carcinoma, melanoma and other solid tumor types. Patients with confirmed IL13Rα2 expression may be eligible for this study. The trial evaluates the safety, dose levels, and potential effectiveness of IL13Rα2-targeting CAR-T cells in treating advanced cancers.

This multisite study, led by **Dr. Anusha Kalbasi** and **Dr. Allison Betof-Warner (Stanford)** in collaboration with **Dr. Antoni Ribas (UCLA)** and **Dr. Yan Xing (City of Hope)**, is now enrolling patients at all three institutions.

If successful, this therapy could offer a new treatment option for patients who have not benefited from standard therapies.

**Who May Be Eligible** – Patients diagnosed with one of the following:

- Neuroendocrine tumors
- Pheochromocytoma and paraganglioma
- Adrenocortical Carcinoma
- Melanoma
- Thyroid cancers
- Other metastatic or treatment-resistant solid tumors

### Pre-Screening Steps

1. Provide consent by phone with a member of the study team.
2. The team will request your tumor sample from the facility where your biopsy or surgery material is stored.
3. Your tissue will be tested for **IL13Rα2 expression** by immunohistochemistry (IHC). Results will be shared with you and your physician.

*Note: Participation in pre-screening does not commit you to join the trial.*

### Contact Information

- Christy Sidhu, CRC, PICI at UCLA | [PICICenterResearch@mednet.ucla.edu](mailto:PICICenterResearch@mednet.ucla.edu)
- Lucie Cutler, CRC, Stanford Medicine | [luciecut@stanford.edu](mailto:luciecut@stanford.edu)
- Claudia Aceves, CRC, City of Hope | [caceves@coh.org](mailto:caceves@coh.org)

### Principal Investigators

- Dr. Antoni Ribas, MD, PhD, UCLA
- Dr. Allison Betof Warner, MD, PhD, Stanford Medicine
- Dr. Yan Xing, MD, PhD, City of Hope